STOCKHOLM 31 January 2018 – As of 31 January 2018, the last trading day of the month, the aggregate number of shares and votes in Karo Pharma AB amounts to 109,555,188. The increase in the number of shares and votes is attributable to the recently completed rights issue of 27,388,797 shares. The rights issue was announced on 8 November 2017.
FOR FURTHER INFORMATION PLEASE CONTACT:
Peter Blom, CEO, 070-655 56 98 or firstname.lastname@example.org
ABOUT KARO PHARMA
Karo Pharma is a specialty pharma company that develops and markets products to pharmacies and directly to healthcare providers. Karo Pharma is listed on Nasdaq Stockholm in the Mid Cap segment.
This information is information that Karo Pharma is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact person set out above, on 31 January 2018 at 03.00 p.m.